Compare GSIT & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSIT | NGNE |
|---|---|---|
| Founded | 1995 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.8M | 327.8M |
| IPO Year | 2004 | 2014 |
| Metric | GSIT | NGNE |
|---|---|---|
| Price | $7.55 | $29.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $63.57 |
| AVG Volume (30 Days) | ★ 1.7M | 124.4K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $25,122,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 22.44 | N/A |
| 52 Week Low | $2.82 | $14.65 |
| 52 Week High | $18.14 | $37.27 |
| Indicator | GSIT | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 41.98 | 57.90 |
| Support Level | $6.99 | $28.37 |
| Resistance Level | $8.99 | $32.02 |
| Average True Range (ATR) | 0.93 | 1.94 |
| MACD | -0.29 | 0.18 |
| Stochastic Oscillator | 12.61 | 83.35 |
GSI Technology Inc is a provider of semiconductor memory solutions. The company develops and markets high-performance memory products, including Very Fast static random access memory, or SRAM, that are incorporated in high-performance networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations, and network access equipment. It sells these products to original equipment manufacturers and customers including Nokia. In addition, it serves the ongoing needs of the military, aerospace, industrial, test and measurement equipment, and automotive and medical markets for high-performance SRAMs. It operates geographically in China, Singapore, the Netherlands, Germany, Rest of the world, and the United States.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.